Pharmafile Logo
Pharmafocus logo
Advanced Search

obesity

Showing 15 posts of 61 posts found.

hsm_mobile_clinical_trial_istock-872676342

FDA approves Wegovy for treatment of MASH in adults with liver fibrosis

August 22, 2025
Medical Communications, Research and Development Hepatology, Novo Nordisk, US Food and Drug Administration, clinical trial, hepatitis, obesity

The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as a treatment for adults with …

News
pills-384846_960_720

Lilly reports positive results from trial of obesity candidate

August 8, 2025
Medical Communications, Research and Development Eli Lilly and Company, Obesity, cardiovascular risk, high blood pressure, obesity

Eli Lilly and Company (Lilly) has announced topline results from its phase 3 ATTAIN-1 trial, showing that orforglipron – a …

News

MetP Pharma releases positive data on intranasal semaglutide administration

July 22, 2025
Research and Development Diabetes, MetP Pharma, Neurology, Obesity, central nervous system, diabetes, obesity, peptides, semaglutide

MetP Pharma has released new data highlighting the advantages of its MetP technology in delivering neuroactive peptides, particularly semaglutide, directly …

News
money-2180330_960_720

Ciloa secures €6.5m from French government to advance obesity and T2 diabetes therapy

July 9, 2025
Research and Development Ciloa, Diabetes, France 2030, Obesity, adiponectin, funding, obesity, type 2 diabetes

French biotech company, Ciloa, has received €6.5m in funding through France 2030 to advance its lead candidate, APN-sEV, targeting obesity …

News
obesity

Pila Pharma raises SEK 20m to advance new oral obesity treatment

July 8, 2025
Research and Development Novo Nordisk, Obesity, Ozempic, Pila Pharma, Wegovy, obesity, semaglutide, type 2 diabetes

Swedish biotech, Pila Pharma, has raised nearly SEK 20m, equivalent to €1.7m in a capital increase to advance the development …

News
weight-2036971_960_720

Novo Nordisk’s therapy delivers significant weight loss in trial

June 25, 2025
Research and Development Novo Nordisk, Obesity, obesity, weight loss, weight-related medical conditions

Novo Nordisk has announced promising results from its phase 3 REDEFINE 1 trial, showing that investigational weight loss therapy, CagriSema, …

News
researchers_credit_neusentis_pfizer

Novo Nordisk unveils new semaglutide data on obesity and heart disease at ECO 2025

May 12, 2025
Research and Development Cardiology, Novo Nordisk, Obesity, Ozempic, cardiometabolic conditions, heart disease, obesity, semaglutide

Danish biopharma, Novo Nordisk, has announced that it will present new data on metabolic and cardiovascular health at the upcoming …

News
body scan

Pfizer selects once-daily obesity drug for advancement

July 12, 2024
Research and Development Obesity, Pfizer Inc, clinical trials, obesity

Pfizer has announced the selection of its preferred once-daily modified release formulation for danuglipron, with a plan to conduct dose …

News

Biophytis gains IND approval from FDA for obesity study

July 11, 2024
Medical Communications Biophytis, IND, Obesity, clinical trial, obesity

Biophytis has announced that it has received investigational new drug (IND) approval from the US Food and Drug Administration (FDA) …

News
national-cancer-institute-l8twzt4ccvq-unsplash_1

Eli Lilly launches digital healthcare process

January 5, 2024
Medical Communications Diabetes, Eli Lilly, Obesity, diabetes, obesity

Eli Lilly has announced its new digital healthcare experience, LillyDirect, which will benefit patients in the US with obesity, migraine …

News

Teva Pharmaceuticals shares phase 3 data for Ajovy as migraine treatment

December 6, 2023
Research and Development Neurology, Teva Pharmaceuticals, ajovy, obesity

Teva Pharmaceuticals has announced data from a post hoc analysis of two phase 3 clinical studies around the effectiveness of …

News

Novo Nordisk acquires Embark Biotech and its lead metabolic programme

August 31, 2023
Business Services Cardiology, Novo Nordisk, Obesity, acquisition, metabolics, obesity

Novo Nordisk has officially acquired the biopharmaceutical company Embark Biotech, along with its lead asset metabolic programme. The teams will …

News
weight-2036971_960_720

UK plans £40m drug trial for Novo Nordisk’s Wegovy to aid NHS in treating obesity

June 7, 2023
Research and Development NHS, Novo Nordisk, Obesity, Wegovy, clinical trial, obesity

The UK Government has announced plans to launch a pilot programme which will provide GPs with Novo Nordisk’s Wegovy (semaglutide), …

News

Novo Nordisk to expand obesity study into oral treatment

April 22, 2021
Novo Nordisk, obesity

Novo Nordisk is planning to initiate a Phase IIIa study of oral semaglutide in obesity, expanding on its Phase IIIa …

News

Novo Nordisk obesity treatment successful in clinical trials

March 24, 2021
Research and Development Novo Nordisk, obesity

New results from Novo Nordisk’s Phase III study on obesity saw clinically relevant weight loss, without weight regain, in people …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025